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ABSTRACT: A range of enantiomerically pure protected side-chain-
ﬂuorinated amino acids has been prepared (13 examples) by treatment of
protected amino acids containing unsaturated side chains with a
combination of Fe(III)/NaBH4 and Selectﬂuor. The modiﬁcation of the
conditions by replacement of Selectﬂuor with NaN3 allowed the
preparation of side-chain azido-substituted amino acids (ﬁve examples), which upon catalytic hydrogenation gave the
corresponding amines, isolated as lactams (four examples). Radical hydration of the unsaturated side chains leading to side-
chain-hydroxylated protected amino acids has also been demonstrated.
■ INTRODUCTION
The synthesis of enantiomerically pure amino acids continues
to attract substantial attention, and the development of new
methods for the preparation of side-chain-functionalized amino
acids is the focus of much eﬀort.1 In particular, the synthesis of
amino acids with side-chain ﬂuorine substitution has been
widely studied,2 speciﬁcally in the context of the preparation of
(S)-γ-ﬂuoroleucine, a component of the Merck Cathepsin K
inhibitor odanacatib.3 An early approach to (S)-γ-ﬂuoroleucine
ethyl ester relied on the use of the Schöllkopf bis-lactim ether.4
The synthetic routes that have been developed more recently
include the use of aspartic acid as a chiral pool starting
material,5 a titanium-catalyzed asymmetric ene-reaction,6 use
of glycine-Schiﬀ base alkylation followed by enzymatic
resolution,7 and more recently direct photochemical ﬂuorina-
tion of leucine itself.8 This followed an earlier indirect method
which employed photochemical bromination of leucine,
followed by treatment with AgF.9 The latter two approaches
rely on the selective radical cleavage of the tertiary C−H bond
of leucine for their success. A complementary method makes
use of AgF/tetra-n-butylammonium ﬂuoride as the ﬂuorine
source, in conjunction with a manganese porphyrin catalyst.10
In previous work, we have reported a single example of the
synthesis of the γ-ﬂuorinated cyclopentylalanine derivative 2a
using the ionic addition of hydrogen ﬂuoride (HF) (using HF-
pyridine) to an unsaturated amino acid 1a (Scheme 1).11 This
compound was a key component of a Cathepsin S inhibitor.
Although this synthetic approach was rather ineﬃcient, largely
due to the in situ tert-butoxycarbonyl (Boc)-deprotection of
the substrate under the conditions of the reaction, it was
nevertheless a very considerable improvement over the
previous method used for making this protected amino acid.12
The report by Barker and Boger on the new radical addition
of HF to unactivated alkenes, using Fe(III)/NaBH4, with
Selectﬂuor as the ﬂuorine source,13 prompted us to revisit our
general strategy. Indeed, after we had completed the majority
of the work reported in this paper, another group reported the
application of the Barker and Boger method to the synthesis of
Fmoc-(S)-γ-ﬂuoroleucine 4 (in presumed 94% enantiomeric
excess (ee), based on the ee of the starting material), using the
2-propenylalanine derivative 3.14 We now report an in-depth
study of this reaction, to assess its generality and scope for the
preparation of side-chain-ﬂuorinated amino acids as well as a
possible extension by trapping the intermediate alkyl radicals
to allow the introduction of other functional groups into the
amino acid side chains, by exploring the use of subsequently
reported variants of the Boger process.15
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Scheme 1. Original Ionic Method for the Preparation of tert-
Fluoride 2a
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■ RESULTS AND DISCUSSION
Preparation of Unsaturated Amino Acids. The initial
goal was to prepare a representative selection of protected
enantiomerically pure unsaturated amino acids, with double
bonds at both the γ- and δ-positions. A range of cyclo-
alkenylalanine derivatives was prepared by room-temperature
Negishi cross-coupling of cycloalkenyl triﬂates (5a−d, 6, and
7) with the serine-derived zinc reagent 8, according to our
previously reported methods from the protected iodoalanine
derivative 9 (Scheme 2, Table 1).16 It was established that
extending the reaction times for the cross-coupling generally
resulted in higher isolated yields of the desired products (1a−
d) than we had previously observed.11,16 In addition, two more
functionalized vinyl triﬂates 6 and 7 were successfully coupled,
giving the corresponding protected amino acids 10 and 11.
Although there is less precedent for the use of vinyl
bromides in the Negishi cross-coupling with zinc reagent 8, a
range of vinyl bromides (12−15) was successfully coupled
under the same conditions that we had employed for coupling
the vinyl triﬂates to give the expected unsaturated amino acids
(16−19) (Scheme 3, Table 2). The cross-coupling reactions of
(E)- and (Z)-2-bromo-2-butene with zinc reagent 8 were
stereospeciﬁc, leading to the isomeric products (E)-18 and
(Z)-18, respectively. Interestingly, the use of an excess of the
commercially available isomeric mixture of 2-bromo-2-butene
(E/Z, 1.9:1, as determined by 1H NMR, with both isomers
used in excess relative to zinc reagent 8) in the cross-coupling
resulted in the formation of a mixture of the products 18 that
was substantially enriched in the (E)-isomer (E/Z, 7:1) (Table
2, entry 5), indicating that the Negishi cross-coupling of the
zinc reagent 8 with (E)-2-bromo-2-butene (E)-14 was faster
than with (Z)-isomer 2-bromo-2-butene (Z)-14 (by a factor of
3.5). This most likely reﬂects a faster rate of oxidative addition
of the less hindered (E)-isomer of compound 14 to Pd. The
most notable example was the successful cross-coupling of zinc
reagent 8 with 1-bromocyclobutene 15 leading to the
cyclobutenyl alanine derivative 19, which is a rare example
of the use of 1-bromocyclobutene in the Negishi cross-
coupling.
A small selection of unsaturated amino acid substrates 20−
22 was prepared by our previously reported method using
copper-catalyzed allylation of the zinc reagent 8 (Scheme 4).17
Again, we observed that extended reaction times at room
temperature resulted, in most cases, in improved yields over
those we had previously observed.
Radical Addition of HF to Unsaturated Amino Acids.
Barker and Boger’s original report contained examples of the
radical HF-addition to terminal alkenes containing an ester or a
protected amine as well as a dipeptide in which the terminal
alkene was incorporated into a tyrosine residue.13 Therefore, it
was reasonable that unsaturated amino acid substrates would
also undergo the reaction. In the event, the application of the
conditions reported by Barker and Boger to the cyclo-
pentenylalanine derivative 1a resulted in the formation of 2a,
identical to the material we had previously prepared,11 but in
substantially higher yield (64%) and without unproductive
protecting group removal and using less toxic reagents
(Scheme 5). The structure of compound 2a was conﬁrmed
by X-ray analysis and showed a hydrogen bond from the
carbamate N−H to the carbamate carbonyl of the neighboring
molecule as well as a very distinct alignment of the C−F bond
with the C−F bond of the closest neighbor.
Scheme 2. Negishi Cross-Coupling with Cycloalkenyl
Triﬂates
Table 1. Negishi Coupling of Zinc Reagent 8 with
Cycloalkenyl Triﬂates
entry substrate X n product yield (%)
1 5a CH2 0 1a 83 (70)
a
2 5b CH2 1 1b 92 (70)
a
3 5c CH2 2 1c 81 (62)
a
4 5d CH2 3 1d 61 (63)
a
5 6 O 1 10 52
6 7 CF2 1 11 90
aYield obtained under previous conditions.11
Scheme 3. Negishi Cross-Coupling with Vinyl Bromides
Table 2. Negishi Coupling of Zinc Reagent 8 with Vinyl
Bromides
entry substrate R1 R2 R3 product yield (%)
1 12 Me H H 16 84
2 13 H Me Me 17 95
3 (E)-14 Me Me H (E)-18 68
4 (Z)-14 Me H Me (Z)-18 72
5 (E,Z)-14 Me Me/H (E,Z)-18 88
6 15 (CH2)2 H 19 79
Scheme 4. Cu(I)-Catalyzed Allylation of Zinc Reagent 8
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We were pleased to ﬁnd that with the exception of the 4,4-
diﬂuorocyclohexen-1-yl alanine derivative 11 (vide infra), the
procedure proved applicable to the other substrates that we
had prepared, giving the desired HF-addition products in good
to excellent yields (Table 3). To establish whether or not the
reaction proceeded without racemization, both enantiomers of
the 3-methyl-3-butenylglycine derivatives 16 and ent-16 were
each separately subjected to the radical HF-addition
conditions; the products 25 and ent-25 were obtained with
high ee (99 and 98%, respectively, as determined by chiral
phase high-performance liquid chromatography (HPLC)),
thus establishing that the reaction did indeed proceed without
racemization. When the two isomeric alkene substrates 17 and
21 were separately subjected to the radical HF-addition
conditions, the same tert-ﬂuoride 26 was obtained, with a
slightly higher yield from the starting material 17 with the
more substituted double bond (cf. entries 9 and 13, Table 3).
When the radical HF-addition was attempted on the 4,4-
diﬂuorocyclohexen-1-yl alanine derivative 11, the conversion
was incomplete and puriﬁcation diﬃcult. We, therefore,
modiﬁed the procedure by increasing the amounts of Fe(III)
and Selectﬂuor and by the dropwise addition of a solution of
NaBH4 (in 0.1 M NaOH) over a period of 6 h, which resulted
in the isolation of the desired product 24 in comparable yield
to that obtained with the other substrates. This modiﬁed
procedure may be successful with other more challenging
substrates. The X-ray crystal structure of compound 24 was
obtained, conﬁrming the structure and showing similar
intermolecular interactions in the solid state to those observed
in the X-ray structure of 2a.
The addition of HF to the substrates 18 and 20 resulted in the
formation of products 27 and 29 each with a new stereogenic
center. In each case, the removal of the Boc-protecting group
with triﬂuoroacetic acid (TFA) to give the corresponding
triﬂuoroacetate salts, 31 and 32, followed by analysis by NMR
methods established that, in each case, the new stereogenic
center had been formed with very low diastereomeric excess
(de) (speciﬁcally less than 5% de), entirely consistent with the
results of Barker and Boger.13
Radical Addition of HN3 to Unsaturated Amino Acids.
Given the eﬃciency of the radical addition of HF to
unsaturated amino acids and the precedent from Leggans et
al. that a combination of Fe(III)/NaBH4 and NaN3 as the
azide source promoted the eﬃcient radical addition of HN3 to
alkenes,15 we have explored the application of this method to
the functionalization of unsaturated amino acids. The
formation of amino acids with side-chain nitrogen functionality
is of interest, since the compounds are analogues of lysine.
Direct application of the literature protocol for the hydro-
azidation of citronellol15 to unsaturated amino acid 16 resulted
in the incomplete conversion of the starting materials.
However, a minor modiﬁcation, in which the excess of
reagents was increased, resulted in a very eﬃcient conversion
of 16 to the corresponding tertiary azide 33. The application of
this modiﬁed method to a representative selection of
unsaturated amino acids resulted, in each case, in the
formation of the expected tertiary azide in good to excellent
yields (Scheme 6, Table 4). The two isomeric alkenes 17 and
21 gave the same tertiary azide 36, with a slightly higher yield
being observed when using the more substituted alkene 17
(Scheme 7), as already observed during the HF-addition to the
same substrates.
Scheme 5. Radical Hydroﬂuorination of
Cyclopentenylalanine 1a
Table 3. Radical Hydroﬂuorination of Unsaturated
Substrates
entry substrate product yield (%)
1 1a 2a 64
2 1b 2b 64
3 1c 2c 70
4 1d 2d 65
5 10 23 54
6 11 24 0 (64)a
7 16 25 84
8 ent-16 ent-25 88
9 17 26 75
10 18 27 63
11 19 28 81
12 20 29 73
13 21 26 62
14 22 30 91
aReaction carried out by increasing the molar equivalents of Fe(III)
and Selectﬂuor and by the dropwise addition of a solution of NaBH4
(in 0.1 M NaOH).
Scheme 6. Radical Hydroazidation of Unsaturated
Substrates
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Each of the azides 33−36 was reduced by catalytic
hydrogenation to give the corresponding free amines, which
underwent spontaneous cyclization to give the corresponding
lactams 38−41, which were each isolated in high yields
(Scheme 8, Table 5). The structure of the lactam 40 was
conﬁrmed by single-crystal X-ray structure analysis.
Radical Alkene Hydration. The ﬁnal transformation that
we brieﬂy investigated was the radical hydration of unsaturated
amino acids using the combination of Fe(III)/NaBH4 and air
as a radical trap.15 Such a process would lead to amino acids
with a side-chain hydroxyl group. The optimization of this
particular radical addition process proved challenging and
appeared to be critically dependent on the means by which the
air was introduced into the reaction mixture. Most reliable
results were obtained when the air was introduced using a
sintered gas inlet, and in two cases (using 16 and 17 as
substrates), moderate yields of the corresponding hydroxylated
amino acids were obtained, albeit isolated as the corresponding
lactone 42 in one case (Scheme 9).
■ CONCLUSIONS
In conclusion, the generality and scope of the radical HF-
addition to unsaturated amino acid substrates have been
established, further demonstrating the functional group
tolerance of the Boger radical hydroﬂuorination process. In
combination with our previously reported methods for the
preparation of unsaturated amino acids (extended to the
Negishi cross-coupling with vinyl bromides in this paper), this
constitutes an eﬀective and direct method for the preparation
of important side-chain-ﬂuorinated amino acid derivatives.
Furthermore, radical hydroazidation of unsaturated amino acid
substrates has been demonstrated, allowing the synthesis of
side-chain amino-substituted amino acids. Finally, radical
hydration of unsaturated amino acid substrates has been
demonstrated, but further work is required to establish the full
scope of this transformation.
■ EXPERIMENTAL SECTION
High-resolution mass spectrometry (HRMS) measurements
were carried out using electrospray (ES) ionization, with a
time-of-ﬂight mass analyzer. IR spectra were recorded as thin
ﬁlms or using attenuated total reﬂection. The synthesis of N-
Boc-β-I-Ala-OMe was accomplished by the literature meth-
ods.18 For the preparation of zinc reagent 8 and general
procedures A, B, and F, ﬂame-dried glassware was used.
Cycloalkenyl triﬂates 5a−d were prepared by general literature
methods19 from the corresponding ketones and used without
puriﬁcation. Triﬂates 6,20 721 and 1-cyclobutenyl bromide 1522
were each prepared by literature methods.
Preparation of Zinc Reagent 8. Zinc powder (3 equiv)
was suspended in dry dimethylformamide (DMF) (3 mL)
under nitrogen, and iodine (nine crystals) was added
immediately. A change in color from colorless to dark brown
and colorless again was observed. N-Boc-β-I-Ala-OMe 9 (1
equiv) was added followed immediately by iodine (three
crystals), the aforementioned color change was observed once
more, and the insertion process was allowed to proceed for
30−60 min.
General Procedure A, Coupling of 8 to Vinyl Triﬂates
and Halides. Immediately after the preparation of 8,
Pd2(dba)3 (2.5 mol %) and SPhos (5.0 mol %) were added
to the reaction vessel along with an excess vinyl halide/triﬂate
(≈1.6 equiv), as indicated in the individual procedures below.
The reaction mixture was stirred under a gentle ﬂow of
nitrogen for 72 h. The reaction mixture was then ﬁltered
through a silica plug eluting with EtOAc. The organic phase
was washed with water (2 × 50 mL) and brine (50 mL). The
organic phase was dried with Na2SO4, ﬁltered, and the solvent
removed under reduced pressure. Puriﬁcation was carried out
by ﬂash column chromatography (EtOAc in petroleum ether
(40−60) mixtures over silica).
Table 4. Radical Hydroazidation of Unsaturated Substrates
entry substrate R1 R2 product yield (%)
1 16 Me H 33 88
2 1a (CH2)3 34 88
3 1b (CH2)4 35 71
4 (E)-18 Me Me 37 63
Scheme 7. Alternative Approaches to Tertiary Azide 36
Scheme 8. Hydrogenation of Azido Amino Acids
Table 5. Hydrogenation of Azides
entry substrate R1 R2 n product yield (%)
1 33 Me Me 1 38 99
2 34 (CH2)4 1 39 93
3 35 (CH2)5 1 40 91
4 36 Me Me 2 41 98
Scheme 9. Radical Hydration of Unsaturated Amino Acids
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Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(cy-
clopent-1-en-1-yl)propanoate 1a. Synthesis was achieved
by general procedure A using zinc dust (0.217 g, 3.32 mmol),
iodine (2 crystals, then 1 crystal), 9 (0.325 g, 0.99 mmol),
Pd2(dba)3 (0.024 g, 0.03 mmol), SPhos (0.023 g, 0.06 mmol),
and 5a (0.375 g, 1.73 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave 1a as a light orange oil (0.220 g, 0.82 mmol,
83%); [α]D
25 +17.0 (c 2.00, CHCl3), [lit. [α]D
22 +13.9 (c 2.09,
CHCl3)];
16
νmax(ATR)/cm
−1 3371, 2974, 2951, 2932, 2848,
1744, 1713, 1501, 1436, 1392, 1365, 1248, 1211, 1160, 1056,
1020, 860, 778, and 759; 1H NMR (CDCl3, 400 MHz) δH 5.47
(s, 1H), 4.98 (d, J = 7.8 Hz, 1H), 4.41 (m, 1H), 3.73 (s, 3H),
2.59 (dd, J = 14.2 Hz, 4.8 Hz, 1H), 2.49 (dd, J = 14.4 Hz, 7.5
Hz, 1H), 2.33−2.16 (m, 4H), 1.86 (apparent quin, J = 7.4 Hz,
2H), 1.44 (s, 9H); 13C NMR (CDCl3, 100 MHz), δC 173.2,
155.2, 139.0, 128.3, 79.8, 52.2, 52.1, 34.7, 34.2, 32.5, 28.3,
23.6; HRMS (ES) m/z: [M + Na]+ calcd for C14H23NO4Na
292.1519; found 292.1523.
The characterization data was consistent with that reported
in the literature.16
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(cy-
clohex-1-en-1-yl)propanoate 1b. Synthesis was achieved
by general procedure A using zinc dust (0.606 g, 9.27 mmol),
iodine (6 crystals, then 4 crystals), 9 (1.013 g, 3.08 mmol),
Pd2(dba)3 (0.068 g, 0.07 mmol), SPhos (0.069 g, 0.17 mmol),
and 5b (1.283 g, 5.57 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave 1b as a light orange oil (0.798 g, 2.82 mmol,
92%); [α]D
24 +14.1 (c 0.99, CHCl3), [lit. [α]D
22 +14.5 (c 1.68,
CHCl3)];
16
νmax(ATR)/cm
−1 3355, 2976, 2929, 2859, 2838,
1744, 1713, 1504, 1437, 1391, 1365, 1275, 1258, 1215, 1161,
1084, 1048, 1020, 920 and 863; 1H NMR (CDCl3, 400 MHz)
δH 5.48 (s, 1H), 4.92 (d, J = 7.6 Hz, 1H), 4.39 (m, 1H), 3.74
(s, 3H), 2.43 (dd, J = 13.5 Hz, 5.2 Hz, 1H), 2.26 (dd, J = 13.5
Hz, 8.6 Hz, 1H), 2.00−1.88 (m, 4H), 1.68−1.52 (m, 4H), 1.45
(s, 9H); 13C NMR (CDCl3, 100 MHz), δC 173.4, 155.2, 132.7,
125.7, 79.8, 52.1, 51.9, 41.4, 28.3, 27.8, 25.3, 22.7, 22.1; HRMS
(ES) m/z: [M + Na]+ calcd for C15H25NO4Na 306.1681;
found 306.1676.
The characterization data was consistent with that reported
in the literature.16
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(cy-
clohept-1-en-1-yl)propanoate 1c. Synthesis was achieved
by general procedure A using zinc dust (0.791 g, 12.10 mmol),
iodine (12 crystals, then 5 crystals), 9 (1.330 g, 4.04 mmol),
Pd2(dba)3 (0.094 g, 0.10 mmol), SPhos (0.112 g, 0.27 mmol),
and 5c (1.609 g, 6.59 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave 1c as a light orange oil (0.981 g, 3.30 mmol,
82%); [α]D
24 +8.4 (c 1.08, CHCl3), [lit. [α]D
22 +7.8 (c 1.15,
CHCl3)];
16
νmax(ATR)/cm
−1 3367, 2975, 2919, 2846, 1744,
1712, 1498, 1438, 1389, 1365, 1248, 1212, 1159, 1050, 1022,
994 and 852; 1H NMR (CDCl3, 400 MHz) δH 5.62 (t, J = 6.2
Hz, 1H), 4.93 (d, J = 7.1 Hz, 1H), 4.34 (m, 1H), 3.73 (s, 3H),
2.46 (dd, J = 13.2 Hz, 5.6 Hz, 1H), 2.27 (dd, J = 13.3 Hz, 8.3
Hz, 1H), 2.14−2.06 (m, 4H), 1.76−1.70 (m, 2H), 1.44−1.35
(m, 13H); 13C NMR (CDCl3, 100 MHz), δC 173.4, 155.2,
139.3, 131.0, 79.8, 52.1, 52.0, 43.4, 32.4, 32.3, 28.5, 28.3, 27.0,
26.5; HRMS (ES) m/z: [M + Na]+ calcd for C16H27NO4Na
320.1838; found 320.1833.
The characterization data was consistent with that reported
in the literature.16
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(cy-
clooct-1-en-1-yl)propanoate 1d. Synthesis was achieved
by general procedure A using zinc dust (0.596 g, 9.11 mmol),
iodine (9 crystals, then 5 crystals), 9 (0.990 g, 3.01 mmol),
Pd2(dba)3 (0.074 g, 0.08 mmol), SPhos (0.066 g, 0.16 mmol),
and 5d (1.311 g, 5.08 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave 1d as a light orange oil (0.572 g, 1.84 mmol,
61%); [α]D
24 +7.8 (c 1.15, CHCl3), [lit. [α]D
22 +9.5 (c 0.53,
CHCl3)];
16
νmax(ATR)/cm
−1 3365, 2977, 2923, 2851, 1745,
1714, 1501, 1469, 1436, 1391, 1365, 1248, 1216, 1160, 1057,
1023, 894, and 861; 1H NMR (CDCl3, 400 MHz) δH 5.42 (t, J
= 8.0 Hz, 1H), 4.90 (d, J = 7.2 Hz, 1H), 4.35 (m, 1H), 3.73 (s,
3H), 2.50 (dd, J = 13.8 Hz, 4.9 Hz, 1H), 2.26 (dd, J = 13.7 Hz,
9.1 Hz, 1H), 2.15−2.08 (m, 4H), 1.54−1.47 (m, 8H), 1.44 (s,
9H); 13C NMR (CDCl3, 100 MHz), δC 173.4, 155.2, 135.6,
128.7, 79.8, 52.1, 52.0, 40.3, 29.7, 28.5, 28.3, 26.4, 26.3, 26.2;
HRMS (ES) m/z: [M + H]+ calcd for C17H30NO4 312.2175;
found 312.2183.
The characterization data was consistent with that reported
in the literature,16 with the exception of the 13C NMR shifts. In
the previous report, a signal at δC 22.8 was assigned to the
compound, but this was not observed in our puriﬁed sample,
and is, therefore, due to an impurity; heteronuclear single
quantum coherence analysis established that the true signal
was, in fact, obscured by the tert-butyl methyl signal.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(3,6-
dihydro-2H-pyran-4-yl)propanoate 10. Synthesis was
achieved by general procedure A using zinc dust (1.484 g,
22.69 mmol), iodine (12 crystals, then 6 crystals), 9 (2.507 g,
7.62 mmol), Pd2(dba)3 (0.168 g, 0.18 mmol), SPhos (0.153 g,
0.37 mmol), and 6 (2.620 g, 11.28 mmol). Puriﬁcation by ﬂash
column chromatography (25% EtOAc in petroleum ether
(40−60), over silica) gave 10 as a colorless oil (1.132 g, 3.97
mmol, 52%); [α]D
25 +18.6 (c 1.02, CHCl3); νmax(ATR)/cm
−1
3340, 3003, 2977, 2930, 2853, 1743, 1709, 1511, 1436, 1391,
1365, 1249, 1215, 1160, 1126, 1054, 1024, 1000, 849 and 752;
1H NMR (CDCl3, 400 MHz) δH 5.52 (m, 1H), 5.00 (d, J = 7.7
Hz, 1H), 4.42 (m, 1H), 4.11 (m, 2H), 3.77 (m, 5H), 2.50 (dd,
J = 13.9 Hz, 4.6 Hz, 1H), 2.32 (dd, J = 14 Hz, 8.5 Hz, 1H),
2.08 (m, 2H), 1.44 (s, 9H); 13C NMR (CDCl3, 100 MHz), δC
173.1, 155.2, 130.9, 124.1, 80.0, 65.4, 64.3, 52.3, 51.7, 40.44,
28.3, 27.9; HRMS (ES) m/z: [M + Na]+ calcd for
C14H23NO5Na 308.1474; found 308.1485.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(4,4-
diﬂuorocyclohex-1-en-1-yl)propanoate 11. Synthesis
was achieved by general procedure A using zinc dust (0.615
g, 9.41 mmol), iodine (10 crystals, then 3 crystals), 9 (1.046 g,
3.18 mmol), Pd2(dba)3 (0.066 g, 0.07 mmol), SPhos (0.075 g,
0.18 mmol), and 7 (1.313 g, 4.93 mmol). Puriﬁcation by ﬂash
column chromatography (10% EtOAc in petroleum ether
(40−60), over silica) gave 11 as a colorless oil (0.914 g, 2.86
mmol, 90%); [α]D
24 +25.6 (c 1.02, CHCl3); νmax(ATR)/cm
−1
3353, 2980, 1744, 1711, 1504, 1437, 1365, 1264, 1250, 1216,
1160, 1108, 1069, 1014, 971, 889, 860, and 777; 1H NMR
(CDCl3, 400 MHz) δH 5.36 (m, 1H), 4.97 (br d, J = 7.9 Hz,
1H), 4.46 (m, 1H), 3.75 (s, 3H), 2.51 (m, 3H), 2.38−2.25 (m,
3H), 2.09−1.98 (m, 2H), 1.45 (s, 9H); 13C NMR (CDCl3, 100
MHz), δC 172.9, 155.1, 132.7, 122.7 (t, J = 240 Hz), 120.4,
80.0, 52.3, 51.8, 40.6, 34.7 (t, J = 27 Hz), 30.3 (t, J = 24 Hz),
28.3, 26.1 (t, J = 5 Hz); 19F{1H} NMR (CDCl3, 377 MHz) δF
−95.7 (d, J = 235 Hz, 1 F), −97.3 (d, J = 235 Hz, 1 F); HRMS
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(ES) m/z: [M + H]+ calcd for C15H24F2NO4 320.1673; found
320.1679.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-4-
methylpent-4-enoate 16. Synthesis was achieved by general
procedure A using zinc dust (1.966 g, 30.07 mmol), iodine (15
crystals, then 6 crystals), 9 (3.292 g, 10.00 mmol), Pd2(dba)3
(0.229 g, 0.25 mmol), SPhos (0.211 g, 0.51 mmol), and 2-
bromopropene 12 (0.9 mL, 1.226 g, 10.13 mmol). Puriﬁcation
by ﬂash column chromatography (10% EtOAc in petroleum
ether (40−60), over silica) gave 16 as a light orange oil (2.051
g, 8.43 mmol, 84%); [α]D
24 +10.5 (c 1.05, CHCl3);
νmax(ATR)/cm
−1 3379, 2977, 2956, 2932, 1744, 1713, 1500,
1437, 1365, 1247, 1215, 1160, 1046, 1020, 895, 861, 779 and
759; 1H NMR (CDCl3, 400 MHz) δH 4.96 (d, J = 6.6 Hz, 1H),
4.86 (s, 1H), 4.76 (s, 1H), 4.41 (m, 1H), 3.73 (s, 3H), 2.52
(dd, J = 13.8 Hz, 5.4 Hz, 1H), 2.37 (dd, J = 13.8 Hz, 8.3 Hz,
1H), 1.74 (s, 3H), 1.44 (s, 9H); 13C NMR (CDCl3, 100
MHz), δC 173.1, 155.3, 140.5, 114.5, 79.9, 52.2, 51.8, 40.7,
28.3, 21.8; HRMS (ES) m/z: [M + Na]+ calcd for
C12H21NO4Na 266.1363; found 266.1365.
Methyl (2R)-2-{[(tert-Butoxy)carbonyl]amino}-4-
methylpent-4-enoate ent-16. Synthesis was achieved by
general procedure A using zinc dust (0.607 g, 9.28 mmol),
iodine (9 crystals, then 3 crystals), (S)-N-Boc-β-I-Ala-OMe
ent-9 (1.027 g, 3.12 mmol), Pd2(dba)3 (0.076 g, 0.08 mmol),
SPhos (0.067 g, 0.16 mmol), and 2-bromopropene 12 (0.45
mL, 0.613 g, 5.07 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave ent-16 as a light orange oil (0.729 g, 3.00
mmol, 96%); [α]D
24 −10.1 (c 1.48, CHCl3).
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-5-
methylhex-4-enoate 17. Synthesis was achieved by general
procedure A using zinc dust (0.594 g, 9.08 mmol), iodine (6
crystals, then 3 crystals), 9 (1.006 g, 3.06 mmol), Pd2(dba)3
(0.070 g, 0.08 mmol), SPhos (0.065 g, 0.16 mmol), and 1-
bromo-2-methyl-1-propene 13 (0.614 g, 4.55 mmol).
Puriﬁcation by ﬂash column chromatography (10% EtOAc in
petroleum ether (40−60), over silica) gave 17 as a light orange
oil (0.748 g, 2.91 mmol, 95%); [α]D
24 +28.6 (c 1.05, CHCl3);
νmax(ATR)/cm
−1 3358, 2976, 2918, 1744, 1702, 1498, 1437,
1366, 1352, 1273, 1248, 1208, 1162, 1111, 1059, 1023, 860
and 754; 1H NMR (CDCl3, 400 MHz) δH 5.02 (m, 2H), 4.34
(m, 1H), 3.72 (s, 3H), 2.53 (m, 1H), 2.41 (m, 1H), 1.70 (d, J
= 0.8 Hz, 3H), 1.6 (s, 3H), 1.43 (s, 9H); 13C NMR (CDCl3,
100 MHz), δC 172.9, 155.3, 136.3, 117.6, 79.8, 53.3, 52.2, 30.9,
28.3, 25.9, 17.8; HRMS (ES) m/z: [M + Na]+ calcd for
C13H23NO4Na 280.1519; found 280.1524.
This reaction was also carried out on a larger scale using 9
(3.292 g, 10.00 mmol) and analogous equivalents of reagents,
giving 17 (2.310 g, 8.98 mmol, 90%).
Methyl (2S,4E)-2-{[(tert-Butoxy)carbonyl]amino}-4-
methylhex-4-enoate (E)-18. Synthesis was achieved by
general procedure A using zinc dust (0.233 g, 3.56 mmol),
iodine (4 crystals, then 2 crystals), 9 (0.339 g, 1.03 mmol),
Pd2(dba)3 (0.026 g, 0.03 mmol), SPhos (0.023 g, 0.06 mmol),
and (E)-2-bromo-2-butene 14 (0.12 mL, 0.159 g, 1.18 mmol).
Puriﬁcation by ﬂash column chromatography (10% EtOAc in
petroleum ether (40−60), over silica) gave (E)-18 as a light
orange oil (0.181 g, 0.70 mmol, 68%); [α]D
24 +10.0 (c 1.20,
CHCl3); νmax(thin ﬁlm, NaCl plates)/cm
−1 3443, 3372, 2978,
2930, 2862, 1747, 1718, 1503, 1438, 1366, 1250, 1218, 1170,
1060 and 1019; 1H NMR (CDCl3, 400 MHz) δH 5.26 (q, J =
6.0 Hz, 1H), 4.91 (d, J = 7.4 Hz, 1H), 4.34 (m, 1H), 3.70 (s,
3H), 2.45 (dd, J = 13.4 Hz, 5.3 Hz, 1H), 2.27 (dd, J = 13.4 Hz,
8.5 Hz, 1H), 1.6 (m, 3H), 1.57 (d, J = 6.7 Hz, 3H), 1.41 (s,
9H); 13C NMR (CDCl3, 100 MHz), δC 173.3, 155.2, 130.7,
123.2, 79.7, 52.1, 52.0, 42.7, 28.3, 15.3, 13.5; HRMS (ES) m/z:
[M + Na]+ calcd for C13H23NO4Na 280.1519; found 280.1521.
Methyl (2S,4E)-2-{[(tert-Butoxy)carbonyl]amino}-4-
methylhex-4-enoate (Z)-18. Synthesis was achieved by
general procedure A using zinc dust (0.623 g, 9.53 mmol),
iodine (10 crystals, then 3 crystals), 9 (1.000 g, 3.04 mmol),
Pd2(dba)3 (0.072 g, 0.08 mmol), SPhos (0.068 g, 0.17 mmol),
and (Z)-2-bromo-2-butene 14 (0.50 mL, 0.666 g, 4.93 mmol).
Puriﬁcation by ﬂash column chromatography (10% EtOAc in
petroleum ether (40−60), over silica) gave (Z)-18 as a light
orange oil (0.564 g, 2.19 mmol, 72%); [α]D
23 +13.7 (c 1.38,
CHCl3); νmax(thin ﬁlm, NaCl plates)/cm
−1 3445, 3373, 2977,
2930, 2865, 1747, 1717, 1505, 1453, 1438, 1367, 1278, 1251,
1208, 1169, 1086, 1052, 1021, 861 and 779; 1H NMR (CDCl3,
400 MHz) δH 5.39 (q, J = 6.6 Hz, 1H), 4.97 (d, J = 7.7 Hz,
1H), 4.40 (m, 1H), 3.72 (s, 3H), 2.52 (dd, J = 13.6 Hz, 6.2 Hz,
1H), 2.42 (dd, J = 13.2 Hz, 7.8 Hz, 1H), 1.68 (m, 3H), 1.56
(d, J = 6.6 Hz, 3H), 1.42 (s, 9H); 13C NMR (CDCl3, 100
MHz), δC 173.3, 155.2, 130.5, 123.5, 79.8, 52.2, 52.0, 34.3,
28.3, 23.3, 13.4; HRMS (ES) m/z: [M + Na]+ calcd for
C13H23NO4Na 280.1519; found 280.1520.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(cy-
clobut-1-en-1-yl)propanoate 19. Synthesis was achieved
by general procedure A using zinc dust (0.592 g, 9.06 mmol),
iodine (9 crystals, then 6 crystals), 9 (0.988 g, 3.00 mmol),
Pd2(dba)3 (0.070 g, 0.08 mmol), SPhos (0.063 g, 0.17 mmol),
and 1-bromo-1-cyclobutene 15 (2.6 M in tetrahydrofuran, 0.38
mL, 0.99 mmol). Puriﬁcation by ﬂash column chromatography
(8% EtOAc in petroleum ether (40−60), over silica) initially
gave the product and N-Boc-Ala-OMe as a mixture. Further
puriﬁcation by ﬂash column chromatography (CH2Cl2, over
silica) gave 19 as a colorless oil (0.201 g, 0.79 mmol, 80%);
[α]D
24 +20.2 (c 1.19, CHCl3); νmax(thin ﬁlm, NaCl plates)/
cm−1 3362, 2978, 2953, 2929, 1745, 1716, 1512, 1438, 1392,
1367, 1250, 1219, 1166, 1052, 1024, and 858; 1H NMR
(CDCl3, 400 MHz) δH 5.82 (s, 1H), 5.08 (d, J = 7.8 Hz, 1H),
4.42 (m, 1H), 3.75 (s, 3H), 2.54−2.36 (br, m, 6H), 1.45 (s,
9H); 13C NMR (CDCl3, 100 MHz), δC 172.9, 155.2, 144.5,
131.6, 79.9, 52.3, 51.9, 34.0, 31.5, 28.3, 27.1; HRMS (ES) m/z:
[M + Na]+ calcd for C13H21NO4Na 278.1363; found 278.1363.
General Procedure B, Reaction of 8 with Allyl
Chlorides. A ﬂask containing CuBr·DMS (10 mol %) was
placed under vacuum and heated vigorously until the gray
CuBr·DMS became light green/yellow. The ﬂask was then
placed under a ﬂow of nitrogen and allowed to cool to room
temperature. This was repeated once more, and the ﬂask was
allowed to cool to room temperature. A prepared solution of 8
in DMF was transferred to the ﬂask containing CuBr·DMS.
Allylic chloride (1.5 equiv) was added, and the reaction stirred
for 72 h at room temperature. The reaction mixture was then
ﬁltered through a silica plug eluting with EtOAc. The organic
phase was washed with water (2 × 50 mL) and brine (50 mL).
The organic phase was dried with Na2SO4, ﬁltered, and the
solvent removed under reduced pressure. The product was
puriﬁed by ﬂash column chromatography (EtOAc in
petroleum ether (40−60) over silica).
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}hex-5-
enoate 20. Synthesis was achieved by general procedure B
using zinc dust (0.993 g, 15.19 mmol), iodine (11 crystals,
then 5 crystals), 9 (1.665 g, 5.06 mmol), CuBr·DMS (0.064 g,
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0.31 mmol), and allyl chloride (0.5 mL, 0.470 g, 6.14 mmol).
Puriﬁcation by ﬂash column chromatography (10% EtOAc in
petroleum ether (40−60), over silica) gave 20 as a colorless oil
(1.030 g, 4.23 mmol, 84%); [α]D
24 +20.0 (c 1.05, CHCl3);
νmax(ATR)/cm
−1 3352, 2978, 2953, 2930, 1742, 1697, 1504,
1437, 1392, 1366, 1247, 1214, 1159, 1049, 1023, 994, 913, 858
and 778; 1H NMR (CDCl3, 400 MHz) δH 5.80 (m, 1H), 5.04
(m, 3H), 4.34 (m, 1H), 3.75 (s, 3H), 2.12 (m, 2H), 1.92 (m,
1H), 1.73 (m, 1H), 1.45 (s, 9H); 13C NMR (CDCl3, 100
MHz), δC 173.3, 155.3, 136.9, 115.7, 79.9, 53.0, 52.3, 32.0,
29.5, 28.3; HRMS (ES) m/z: [M + Na]+ calcd for
C12H21NO4Na 266.1363; found 266.1369.
This characterization data is consistent with that previously
reported.23
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-5-
methylhex-5-enoate 21. Synthesis was achieved by general
procedure B using zinc dust (1.033 g, 15.80 mmol), iodine (15
crystals, then 6 crystals), 9 (1.648 g, 5.00 mmol), CuBr·DMS
(0.105 g, 0.51 mmol), and 3-chloro-2-methyl-1-propene (1.038
g, 11.46 mmol). Puriﬁcation by ﬂash column chromatography
(10% EtOAc in petroleum ether (40−60), over silica) gave 21
as a colorless oil (1.009 g, 3.92 mmol, 78%); [α]D
24 +21.6 (c
1.11, CHCl3); νmax(ATR)/cm
−1 3358, 2978, 2160, 1978, 1743,
1713, 1506, 1450, 1365, 1276, 1258, 1212, 1163, 1051, 1023
and 888; 1H NMR (CDCl3, 400 MHz) δH 5.07 (d, J = 7.9 Hz,
1H), 4.75 (br s, 1H), 4.70 (br s, 1H), 4.33 (m, 1H), 3.75 (s,
3H), 2.09−1.88 (br m, 3H), 1.79−1.72 (br m, 4H), 1.45 (s,
9H); 13C NMR (CDCl3, 100 MHz), δC 173.3, 155.3, 144.3,
110.7, 79.9, 53.2, 52.2, 33.3, 30.7, 28.3, 22.5; HRMS (ES) m/z:
[M + H]+ calcd for C13H24NO4 258.1705; found 258.1710.
1,9-Dimethyl (2S,8S)-2,8-Bis({[(tert-butoxy)carbonyl]-
amino})-5-methylidenenonanedioate 22. Synthesis was
achieved by general procedure B using zinc dust (0.495 g, 7.57
mmol), iodine (10 crystals, then 5 crystals), 9 (0.828 g, 2.52
mmol), CuBr·DMS (0.058 g, 0.28 mmol), and 3-chloro-2-
chloromethyl-1-propene (0.125 mL, 0.116 g, 0.93 mmol).
Puriﬁcation by ﬂash column chromatography (25% EtOAc in
petroleum ether (40−60), over silica) gave 22 as a colorless oil
(0.393 g, 0.86 mmol, 92%); [α]D
22 +27.5 (c 1.09, CHCl3);
νmax(ATR)/cm
−1 3358, 2976, 2933, 1739, 1694, 1647, 1513,
1452, 1437, 1392, 1365, 1273, 1248, 1213, 1160, 1049, 1025,
892, and 864; 1H NMR (CDCl3, 400 MHz) δH 5.08 (d, J =
8.0, 2H), 4.77 (s, 2H), 4.31−4.26 (m, 2H), 3.72 (s, 6H),
2.07−1.90 (m, 6H), 1.76−1.67 (m, 2H), 1.43 (s, 18H); 13C
NMR (CDCl3, 100 MHz), δC 173.2, 155.3, 146.5, 110.6, 79.9,
53.1, 52.2, 31.6, 30.8, 28.3; HRMS (ES) m/z: [M + H]+ calcd
for C22H39N2O8 459.2706; found 459.2690.
General Procedure C, Radical Fluorination. The
protected amino acid (1 equiv) was dissolved in MeCN (20
mL) and placed under nitrogen. The solution was cooled to 0
°C. Fe2(ox)3 (15 wt % solution) and deionized water (18 mL)
were added. Selectﬂuor was then added followed by NaBH4,
which was added in two portions with ≈2 min between each
addition. The reaction was stirred for 45 min at 0 °C. Conc.
NH4OH solution (4 mL) was added. The reaction mixture was
stirred for 1 min. The aqueous layer was extracted with CH2Cl2
(3 × 50 mL), the combined organic layers were dried with
Na2SO4, ﬁltered, and the solvent removed under reduced
pressure. The product was isolated by column chromatography
(EtOAc in petroleum ether (40−60) mixtures over silica).
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(1-
ﬂuorocyclopentyl)propanoate 2a. Synthesis was achieved
by general procedure C using 1a (0.128 g, 0.48 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (3.283 g, 1.02 mmol),
Selectﬂuor (0.367 g, 1.04 mmol), and NaBH4 (0.069 g, 1.82
mmol; 0.066 g, 1.74 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave 2a as a colorless oil (0.088 g, 0.30 mmol,
63%); crystals were obtained by dissolving in hot pentane and
leaving the solution to slowly evaporate; mp 43−46 °C; [α]D
23
+5.0 (c 1.20, CHCl3); νmax(ATR)/cm
−1 3355, 2972, 1752,
1685, 1531, 1438, 1391, 1366, 1337, 1318, 1289, 1205, 1161,
1130, 1055, 1028, 996, 960, 866, 792, 778, and 761; 1H NMR
(CDCl3, 400 MHz) δH 5.26 (d, J = 6.0 Hz, 1H), 4.44 (m, 1H),
3.73 (s, 3H), 2.32−1.96 (br m, 4H), 1.79 (m, 2H), 1.69−1.52
(br m, 4H), 1.43 (s, 9H); 13C NMR (CDCl3, 100 MHz), δC
173.1, 155.2, 105.9 (d, J = 173 Hz), 79.9, 52.3, 51.3, 39.9 (d, J
= 23 Hz), 37.8 (d, J = 24 Hz), 37.7 (d, J = 24 Hz), 28.3, 23.6,
23.5; 19F{1H} NMR (CDCl3, 377 MHz) δF −142.8 (s);
HRMS (ES) m/z: [M + Na]+ calcd for C14H24FNO4Na
312.1582; found 312.1573.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(1-
ﬂuorocyclohexyl)propanoate 2b. Synthesis was achieved
by general procedure C using 1b (0.155 g, 0.55 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (3.318 g, 1.03 mmol),
Selectﬂuor (0.365 g, 1.03 mmol), and NaBH4 (0.066 g, 1.74
mmol; 0.070 g, 1.85 mmol). Puriﬁcation by ﬂash column
chromatography (8% EtOAc in petroleum ether (40−60), over
silica) gave 2b as a colorless oil (0.107 g, 0.35 mmol, 64%);
[α]D
24 +2.0 (c 1.13, CHCl3); νmax(ATR)/cm
−1 3367, 2936,
2866, 1746, 1710, 1504, 1437, 1392, 1366, 1276, 1257, 1212,
1160, 1114, 1049, 1023, 965, 946, 917, 865, and 827; 1H NMR
(CDCl3, 400 MHz) δH 5.20 (d, J = 4.6 Hz, 1H), 4.43 (m, 1H),
3.74 (s, 3H), 2.16−1.87 (br m, 4H), 1.64−1.24 (m, 17H); 13C
NMR (CDCl3, 100 MHz), δC 173.3, 155.3, 95.7 (d, J = 170
Hz), 79.9, 52.4, 50.2, 41.4 (d, J = 22 Hz), 35.6 (d, J = 22 Hz),
34.7 (d, J = 22 Hz), 28.3, 25.1, 21.8; 19F NMR (CDCl3, 377
MHz) δF −153.7 (br s); HRMS (ES) m/z: [M + Na]
+ calcd
for C15H26FNO4Na 326.1744; found 326.1736.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(1-
ﬂuorocycloheptyl)propanoate 2c. Synthesis was achieved
by general procedure C using 1c (0.148 g, 0.50 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (3.236 g, 1.00 mmol),
Selectﬂuor (0.368 g, 1.04 mmol), and NaBH4 (0.061 g, 1.61
mmol; 0.063 g, 1.67 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave 2c as a colorless oil (0.112 g, 0.35 mmol,
70%); [α]D
24 +1.8 (c 1.14, CHCl3); νmax(ATR)/cm
−1 3362,
2931, 2858, 1744, 1712, 1502, 1458, 1438, 1389, 1365, 1252,
1204, 1159, 1050, 1022, 961, 861, and 836; 1H NMR (CDCl3,
400 MHz) δH 5.21 (m, 1H), 4.41 (m, 1H), 3.75 (s, 3H), 1.72
(br m, 23H); 13C NMR (CDCl3, 100 MHz), δC 173.3, 155.3,
100.1 (d, J = 169 Hz), 80.0, 52.4, 50.6, 42.4 (d, J = 22 Hz),
39.2 (d, J = 24 Hz), 38.0 (d, J = 24 Hz), 29.55, 29.51, 28.3,
22.1 (d, J = 7 Hz), 22.0 (d, J = 5 Hz); 19F{1H} NMR (CDCl3,
377 MHz) δF −137.7; HRMS (ES) m/z: [M + Na]
+ calcd for
C16H28FNO4Na 340.1900; found 340.1913.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(1-
ﬂuorocyclooctyl)propanoate 2d. Synthesis was achieved
by general procedure C using 1d (0.171 g, 0.55 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (3.320 g, 1.03 mmol),
Selectﬂuor (0.367 g, 1.04 mmol), and NaBH4 (0.070 g, 1.85
mmol; 0.065 g, 1.72 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave 2d as a colorless oil (0.120 g, 0.36 mmol,
65%); [α]D
25 +3.8 (c 1.58, CHCl3); νmax(ATR)/cm
−1 3363,
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2921, 2857, 1747, 1713, 1504, 1475, 1436, 1391, 1366, 1276,
1248, 1213, 1160, 1048, 1026, 917, 864, and 829; 1H NMR
(CDCl3, 400 MHz) δH 5.24 (d, J = 4.2 Hz, 1H), 4.40 (m, 1H),
3.74 (s, 3H), 1.71 (br m, 25H); 13C NMR (CDCl3, 100 MHz),
δC 173.3, 155.3, 99.8 (d, J = 167 Hz), 79.9, 52.4, 50.6, 40.3 (d,
J = 21 Hz), 34.7 (d, J = 24 Hz), 33.2 (d, J = 24 Hz), 28.3, 28.0,
27.8, 24.9, 21.9 (d, J = 8 Hz), 21.8 (d, J = 8 Hz); 19F{1H}
NMR (CDCl3, 377 MHz) δF −137.2; HRMS (ES) m/z: [M +
Na]+ calcd for C17H30FNO4Na 354.2057; found 354.2067.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(4-
ﬂuorooxan-4-yl)propanoate 23. Synthesis was achieved
by general procedure C using 10 (0.144 g, 0.50 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (3.247 g, 1.01 mmol),
Selectﬂuor (0.355 g, 1.00 mmol), and NaBH4 (0.061 g, 1.61
mmol; 0.067 g, 1.77 mmol). Puriﬁcation by ﬂash column
chromatography (15−25% EtOAc in petroleum ether (40−
60), over silica) gave 23 as a colorless oil (0.090 g, 0.29 mmol,
58%); [α]D
24 +7.0 (c 1.42, CHCl3); νmax(ATR)/cm
−1 3347,
2958, 2930, 2867, 1747, 1710, 1513, 1436, 1392, 1366, 1280,
1249, 1214, 1160, 1102, 1048, 1014, 985, 838, 780, and 758;
1H NMR (CDCl3, 400 MHz) δH 5.17 (d, J = 6.7 Hz, 1H), 4.50
(m, 1H), 3.65−3.69 (m, 7H), 2.23−1.62 (m, 6H), 1.46 (s,
9H); 13C NMR (CDCl3, 100 MHz), δC 173.0, 155.2, 92.7 (d, J
= 172 Hz), 80.1, 63.4, 52.5, 49.7, 41.9 (d, J = 21 Hz), 35.6 (d, J
= 22 Hz), 35.1 (d, J = 22 Hz), 28.3; 19F{1H} NMR (CDCl3,
377 MHz) δF −159.8; HRMS (ES) m/z: [M + Na]
+ calcd for
C14H24FNO5Na 328.1536; found 328.1551.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-
(1,4,4-triﬂuorocyclohexyl)propanoate 24. Synthesis was
achieved by general procedure C with the modiﬁcations
discussed in the Results and Discussion section using 11
(0.161 g, 0.50 mmol), Fe2(ox)3·6H2O (15 wt % solution)
(3.289 g, 1.02 mmol), Selectﬂuor (0.905 g, 2.55 mmol), and
NaBH4 (0.305 g, 8.06 mmol) in 0.1 M NaOH solution (30
mL) added over 6 h. Puriﬁcation by ﬂash column
chromatography (13% EtOAc in petroleum ether (40−60),
over silica) gave the product as a colorless oil that solidiﬁed on
standing to give 24 as a white solid. Recrystallized from hot
pentane (0.110 g, 0.32 mmol, 64%); mp 67−69 °C; [α]D
24
+1.9 (c 1.03, CHCl3); νmax(ATR)/cm
−1 3378, 3010, 2970,
2936, 2862, 2339, 1763, 1689, 1530, 1442, 1389, 1367, 1343,
1316, 1270, 1256, 1221, 1162, 1122, 1095, 1053, 1022, 992,
963, 913, 893, 865, and 844; 1H NMR (CDCl3, 400 MHz) δH
5.16 (d, J = 7.5 Hz, 1H), 4.48 (m, 1H), 3.76 (s, 3H), 2.20−
2.00 (br m, 8H), 1.82−1.65 (br m, 2H), 1.45 (s, 9H); 13C
NMR (CDCl3, 100 MHz), δC 172.9, 155.2, 122.6 (dd, J = 243
Hz, 238 Hz), 93.5 (d, J = 173 Hz), 80.2, 52.6, 50.1, 41.3 (d, J =
21 Hz), 31.8 (dd, J = 10 Hz, 10 Hz), 31.5 (dd, J = 10 Hz, 10
Hz), 29.2 (apparent t, J = 25 Hz), 28.3; 19F{1H} NMR
(CDCl3, 377 MHz) δF −93.4 (d, J = 238 Hz, 1 F), −105.0 (d, J
= 238 Hz, 1 F), −162.6 (s, 1 F); HRMS (ES) m/z: [M + Na]+
calcd for C15H24F3NO4Na 362.1555; found 362.1541.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-4-ﬂuo-
ro-4-methylpentanoate 25. Synthesis was achieved by
general procedure C using 16 (0.119 g, 0.49 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (3.247 g, 1.01 mmol),
Selectﬂuor (0.357 g, 1.01 mmol), and NaBH4 (0.066 g, 1.74
mmol; 0.059 g, 1.56 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave 25 as a colorless oil, which solidiﬁed on
standing (0.107 g, 0.41 mmol, 84%); mp 37−40 °C; [α]D
24
−2.5 (c 1.18, CHCl3); νmax(ATR)/cm
−1 3373, 2980, 2957,
2917, 2849, 1746, 1712, 1505, 1438, 1390, 1366, 1249, 1206,
1161, 1049, 1027, 990, 889, 866, 849, 797, and 781; 1H NMR
(CDCl3, 400 MHz) δH 5.20 (d, J = 6.2 Hz, 1H), 4.41 (m, 1H),
3.73 (s, 3H), 2.17−1.94 (br m, 2H), 1.43 (s, 9H), 1.41 (d, J =
21.5 Hz, 6H); 13C NMR (CDCl3, 100 MHz), δC 173.1, 155.3,
95.0 (d, J = 166 Hz), 80.0, 52.4, 50.8, 42.6 (d, J = 22 Hz), 28.3,
27.1 (d, J = 25 Hz), 26.5 (d, J = 25 Hz); 19F{1H} NMR
(CDCl3, 377 MHz) δF −136.6 (s); HRMS (ES) m/z: [M +
Na]+ calcd for C12H22FNO4Na 286.1425; found 286.1427.
Methyl (2R)-2-{[(tert-Butoxy)carbonyl]amino}-4-ﬂuo-
ro-4-methylpentanoate ent-25. Synthesis was achieved by
general procedure C using ent-16 (0.124 g, 0.51 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (3.330 g, 1.03 mmol),
Selectﬂuor (0.379 g, 1.07 mmol), and NaBH4 (0.058 g, 1.54
mmol; 0.064 g, 1.69 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave ent-25 as a colorless oil, which solidiﬁed on
standing (0.118 g, 0.45 mmol, 88%); mp 38−40 °C; [α]D
24
+3.1 (c 1.31, CHCl3).
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-5-ﬂuo-
ro-5-methylhexanoate 26. Synthesis was achieved by
general procedure C using 17 (0.130 g, 0.51 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (3.109 g, 0.96 mmol),
Selectﬂuor (0.368 g, 1.04 mmol), and NaBH4 (0.064 g, 1.70
mmol; 0.061 g, 1.60 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave 26 as a colorless oil (0.104 g, 0.38 mmol,
75%); [α]D
24 +14.0 (c 1.07, CHCl3); νmax(ATR)/cm
−1 3358,
3004, 2980, 2933, 1743, 1712, 1512, 1454, 1438, 1389, 1366,
1276, 1260, 1210, 1160, 1053, 1027, and 875; 1H NMR
(CDCl3, 400 MHz) δH 5.08 (d, J = 8.0 Hz, 1H), 4.30 (m, 1H),
3.75 (s, 3H), 2.00−1.91 (br m, 1H), 1.78−1.59 (br m, 3H),
1.43 (s, 9H), 1.34 (d, J = 21.3 Hz, 6H); 13C NMR (CDCl3,
100 MHz), δC 173.1, 155.4, 94.9 (d, J = 166 Hz), 79.9, 53.3,
52.3, 36.78 (d, J = 23 Hz), 28.3, 27.14 (d, J = 5 Hz), 26.7 (d, J
= 24 Hz), 26.5 (d, J = 24 Hz); 19F{1H} NMR (CDCl3, 377
MHz) δF −139.5 (s); HRMS (ES) m/z: [M + H]
+ calcd for
C13H24FNO4 278.1768; found 278.1756.
Synthesis of 26 was also achieved by general procedure C
using 21 (0.133 g, 0.52 mmol), Fe2(ox)3·6H2O (15 wt %
solution) (3.285 g, 1.02 mmol), Selectﬂuor (0.358 g, 1.01
mmol), and NaBH4 (0.067 g, 1.77 mmol; 0.067 g, 1.77 mmol).
Puriﬁcation by ﬂash column chromatography (10% EtOAc in
petroleum ether (40−60), over silica) gave 26 as a colorless oil
(0.090 g, 0.32 mmol, 62%), identical to that isolated above.
Methyl (2S,4RS)-2-{[(tert-Butoxy)carbonyl]amino}-4-
ﬂuoro-4-methylhexanoate 27. Synthesis was achieved by
general procedure C using (E/Z)-18 (7:1, E/Z) (0.132 g, 0.51
mmol), Fe2(ox)3·6H2O (15 wt % solution) (3.460 g, 1.07
mmol), Selectﬂuor (0.358 g, 1.01 mmol), and NaBH4 (0.062 g,
1.64 mmol; 0.061 g, 1.61 mmol). Puriﬁcation by ﬂash column
chromatography (8% EtOAc in petroleum ether (40−60), over
silica) gave 27 as a colorless oil as a mixture of diastereomers
(0.114 g, 0.41 mmol, 80%); νmax(thin ﬁlm, NaCl plates)/cm
−1
3371, 2979, 2937, 2889, 1750, 1716, 1513, 1456, 1438, 1386,
1367, 1280, 1249, 1208, 1167, 1056, 1026, 865, and 781; 1H
NMR (CDCl3, 400 MHz) δH 5.19 (m, 1H), 4.40 (m, 1H),
3.73 (s, 3H), 2.01 (m, 2H), 1.66 (m, 2H), 1.43 (s, 9H), 1.36
(d, J = 21.9 Hz, 3H), 0.93 (td, J = 7.5 Hz, 1.4 Hz, 3H); 13C
NMR (CDCl3, 100 MHz), δC 173.2, 155.3, 97.2 (d, J = 168
Hz), 97.1 (d, J = 168 Hz), 79.9, 52.4, 50.6 (d, J = 24 Hz), 40.8
(d, J = 22 Hz), 40.3 (d, J = 22 Hz), 33.1 (d, J = 23 Hz), 32.3
(d, J = 23 Hz), 28.3, 23.7 (d, J = 25 Hz), 23.2 (d, J = 25 Hz),
8.0 (d, J = 7 Hz), 7.8 (d, J = 7 Hz); 19F{1H} NMR (CDCl3,
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377 MHz) δF −144.3 (s), −144.6 (s); HRMS (ES) m/z: [M +
Na]+ calcd for C13H24FNO4Na 300.1582; found 300.1586.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(1-
ﬂuorocyclobutyl)propanoate 28. Synthesis was achieved
by general procedure C using 19 (0.135 g, 0.53 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (3.289 g, 1.02 mmol),
Selectﬂuor (0.378 g, 1.07 mmol), and NaBH4 (0.068 g, 1.80
mmol; 0.066 g, 1.74 mmol). Puriﬁcation by ﬂash column
chromatography (8% EtOAc in petroleum ether (40−60), over
silica) gave 28 as a colorless oil, which solidiﬁes on standing
(0.118 g, 0.43 mmol, 81%); mp 52−54 °C; [α]D
25 +7.6 (c
1.19, CHCl3); νmax(ATR)/cm
−1 3362, 2982, 2941, 1755, 1686,
1510, 1457, 1440, 1393, 1365, 1291, 1250, 1219, 1158, 1124,
1093, 1048, 1021, 980, 949, 909, 862, 874, 790, 777, and 758;
1H NMR (CDCl3, 400 MHz) δH 5.22 (d, J = 7.0 Hz, 1H), 4.43
(m, 1H), 3.73 (s, 3H), 2.39−2.13 (m, 6H), 1.91−1.82 (m,
1H), 1.60−1.52 (m, 1H), 1.43 (s, 9H); 13C NMR (CDCl3, 100
MHz), δC 173.0, 155.2, 96.8 (d, J = 210 Hz), 79.9, 52.4, 50.5,
38.7 (d, J = 22 Hz), 33.9 (d, J = 22 Hz), 33.7 (d, J = 22 Hz),
28.3, 12.1 (d, J = 12 Hz); 19F{1H} NMR (CDCl3, 377 MHz)
δF −132.3 (s); HRMS (ES) m/z: [M + Na]
+ calcd for
C13H22FNO4Na 298.1425; found 298.1425.
Methyl (2S,5RS)-2-{[(tert-Butoxy)carbonyl]amino}-5-
ﬂuorohexanoate 29. Synthesis was achieved by general
procedure C using 20 (0.123 g, 0.51 mmol), Fe2(ox)3·6H2O
(15 wt % solution) (3.253 g, 1.01 mmol), Selectﬂuor (0.363 g,
1.02 mmol), and NaBH4 (0.064 g, 1.69 mmol; 0.061 g, 1.61
mmol). Puriﬁcation by ﬂash column chromatography (10%
EtOAc in petroleum ether (40−60), over silica) gave 29 as a
colorless oil as a mixture of diastereomers (0.097 g, 0.37 mmol,
73%); [α]D
24 +10.0 (c 1.75, CHCl3); νmax(ATR)/cm
−1 3346,
2978, 2933, 1743, 1705, 1508, 1451, 1391, 1366, 1296, 1247,
1214, 1159, 1049, 1020, 923, 838, and 780; 1H NMR (CDCl3,
400 MHz) δH 5.09 (d, J = 6.6 Hz, 1H), 4.76−4.54 (br m, 1H),
4.32 (m, 1H), 3.74 (s, 3H), 2.07−1.51 (br, m, 4H), 1.44 (s,
9H), 1.32 (dd, J = 23.9 Hz, 6.2 Hz, 3H); 13C NMR (CDCl3,
100 MHz), δC 173.1, 155.4, 90.0 (d, J = 165 Hz), 90.3 (d, J =
166 Hz), 79.9, 53.2, 52.9, 52.33, 52.31, 32.7 (d, J = 21 Hz),
32.6 (d, J = 21 Hz), 28.4 (d, J = 4 Hz) 28.3, 21.0 (d, J = 23
Hz), 20.9 (d, J = 23 Hz); 19F{1H} NMR (CDCl3, 377 MHz)
δF −173.7 (s), −174.1 (s); HRMS (ES) m/z: [M + H]
+ calcd
for C12H23FNO4 264.1611; found 264.1621.
1,9-Dimethyl (2S,8S)-2,8-Bis({[(tert-butoxy)carbonyl]-
amino})-5-ﬂuoro-5-methylnonane-dioate 30. Synthesis
was achieved by general procedure C using 22 (0.251 g,
0.55 mmol), Fe2(ox)3·6H2O (15 wt % solution) (3.231 g, 1.00
mmol), Selectﬂuor (0.361 g, 1.02 mmol), and NaBH4 (0.065 g,
1.72 mmol; 0.064 g, 1.69 mmol). Puriﬁcation by ﬂash column
chromatography (20% EtOAc in petroleum ether (40−60),
over silica) gave 30 as a colorless oil (0.237 g, 0.50 mmol,
91%); [α]D
25 +17.8 (c 1.01, CHCl3); νmax(ATR)/cm
−1 3358,
2978, 2937, 2159, 2031, 1978, 1740, 1694, 1514, 1454, 1438,
1392, 1365, 1276, 1255, 1211, 1158, 1049, 1024, 881, and 856;
1H NMR (CDCl3, 400 MHz) δH 5.10 (d, J = 8.1 Hz, 2H), 4.29
(m, 2H), 3.74 (s, 6H), 1.91 (br m, 2H), 1.63 (br m, 6H), 1.44
(s, 18H), 1.27 (d, J = 21.6 Hz, 3H); 13C NMR (CDCl3, 100
MHz), δC 173.0, 155.4, 95.9 (d, J = 170 Hz), 80.0, 53.3, 52.4,
35.2 (d, J = 23 Hz), 35.0 (d, J = 23 Hz), 28.3, 26.82 (d, J = 6
Hz), 26.76 (d, J = 6 Hz), 23.9 (d, J = 25 Hz); 19F{1H} NMR
(CDCl3, 377 MHz) δF −147.1 (s); HRMS (ES) m/z: [M +
H]+ calcd for C22H40FN2O8 479.2769; found 479.2774.
General Procedure D, NHBoc Deprotection. The Boc-
protected amino acid was dissolved in CH2Cl2 (3 mL), TFA (3
mL) was added, and the solution was stirred overnight. The
mixture was concentrated under reduced pressure and the
residue redissolved in 1:1 toluene/MeOH (6 mL), which was
removed under reduced pressure; this process was repeated
twice more to aﬀord the product as the TFA salt without
further puriﬁcation.
Methyl (2S,4RS)-2-Ammonium-4-ﬂuoro-4-methylhex-
anoate Triﬂuoroacetate 31. Synthesis was achieved by
general procedure D using 27 (0.030 g, 0.11 mmol), CH2Cl2/
TFA (1:1, 6 mL) and isolated without further puriﬁcation gave
31 as a colorless oil as a mixture of diastereomers (0.031 g,
0.11 mmol, >99%); νmax(thin ﬁlm, NaCl plates)/cm
−1 3445,
2962, 2666, 1751, 1675, 1631, 1533, 1441, 1384, 1240, 1203,
1138, 1034, 927, 838, and 800; 1H NMR (CDCl3, 400 MHz)
δH 8.42 (br s, 3H), 4.78−4.58 (br m, 1H), 4.07−4.00 (br m,
1H), 3.82 (s, 3H), 2.19−1.68 (br m, 4H), 1.34 (dd, J = 24.0
Hz, 5.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz), δC 169.9,
162.3 (q, J = 36.8 Hz), 90.2 (d, J = 165.6 Hz), 89.9 (d, J =
165.7 Hz), 53.3, 52.9, 52.7, 32.0 (d, J = 21.3 Hz), 31.6 (d, J =
21.1 Hz), 26.4 (d, J = 3.8 Hz), 26.1 (d, J = 3.8 Hz), 20.6 (d, J =
22.4 Hz), 20.5 (d, J = 22.4 Hz); 19F{1H} NMR (CDCl3, 377
MHz) δF −76.0 (s, 3 F), −174.6 (s, 0.46 F), −175.0 (s, 0.49
F); 19F NMR (CDCl3, 377 MHz) δF −76.0 (s, 3 F), −174.7
(m, 0.98 F); HRMS (ES) m/z: [M + H]+ calcd for
C7H15FNO2 164.1081; found 164.1081.
Methyl (2S,5RS)-2-Ammonium-5-ﬂuorohexanoate
Triﬂuoroacetate 32. Synthesis was achieved by general
procedure D using 29 (0.019 g, 0.07 mmol), CH2Cl2/TFA
(1:1, 6 mL) and isolated without further puriﬁcation gave 32
as a colorless oil as a mixture of diastereomers (0.020 g, 0.07
mmol, 96%); νmax(thin ﬁlm, NaCl plates)/cm
−1 3423, 2980,
1754, 1678, 1533, 1442, 1385, 1299, 1237, 1204, 1137, 1055,
997, 949, 886, 838, and 801; 1H NMR (CDCl3, 400 MHz) δH
7.39 (br m, 3H), 4.26 (m, 1H), 3.81 (s, 3H), 2.44−2.14 (m,
2H), 1.84−1.59 (m, 2H), 1.42 (d, J = 22.0 Hz, 3H), 0.96 (t, J
= 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz), δC 169.9, 169.7,
97.9 (d, J = 166.6 Hz), 97.6 (d, J = 166.8 Hz), 53.5, 53.4, 50.0,
49.8, 38.9 (d, J = 20.8 Hz), 38.8 (d, J = 20.5 Hz), 33.2 (d, J =
23.0 Hz), 31.6 (d, J = 23.4 Hz), 23.6 (d, J = 24.2 Hz), 22.5 (d,
J = 24.8 Hz), 7.8 (d, J = 7.9 Hz), 7.6 (d, J = 7.3 Hz); 19F{1H}
NMR (CDCl3, 377 MHz) δF −75.8 (s, 3 F), −146.0 (s, 0.5 F),
−147.4 (s, 0.48 F); 19F NMR (CDCl3, 377 MHz) δF −75.8 (s,
3 F), −146.1 (m, 0.49 F), −147.4 (m, 0.47 F); HRMS (ES)
m/z: [M + H]+ calcd for C8H16FNO2 178.1238; found
178.1240.
General Procedure E, Radical Hydroazidation. The
protected unsaturated amino acid was dissolved in MeCN (20
mL), and the solution was cooled to 0 °C. Fe2(ox)3·6H2O (15
wt % solution) was added followed by deionized water (18
mL), NaN3 was then added followed by NaBH4, which was
added in eight portions with ≈2 min between each addition.
The reaction was stirred for 45 min at 0 °C. Conc. NH4OH
solution (30 mL) was added. The reaction mixture was stirred
for 1 min. The aqueous phase was extracted with CH2Cl2 (3 ×
50 mL), the combined organic layers were dried with Na2SO4,
ﬁltered, and the solvent removed under reduced pressure. The
product was puriﬁed by ﬂash column chromatography (EtOAc
in petroleum ether (40−60) mixtures over silica).
Methyl (2S)-4-Azido-2-{[(tert-butoxy)carbonyl]-
amino}-4-methylpentanoate 33. Synthesis was achieved
by general procedure E using 16 (0.127 g, 0.52 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (7.698 g, 2.39 mmol),
NaN3 (0.125 g, 1.92 mmol), and NaBH4 (0.066 g, 1.74 mmol;
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0.078 g, 2.06 mmol; 0.067 g, 1.77 mmol; 0.073 g, 1.93 mmol).
Puriﬁcation by ﬂash column chromatography (10% EtOAc in
petroleum ether (40−60), over silica) gave 33 as a colorless oil
(0.133 g, 0.46 mmol, 88%); [α]D
24 +11.6 (c 0.86, CHCl3);
νmax(thin ﬁlm, NaCl plates)/cm
−1 3364, 2978, 2932, 2851,
2100, 1747, 1716, 1512, 1456, 1438, 1392, 1368, 1252, 1218,
1167, 1051, 1028, 994, 863, and 760; 1H NMR (CDCl3, 400
MHz) δH 5.21 (d, J = 7.7 Hz, 1H), 4.40 (m, 1H), 3.74 (s, 3H),
1.97 (dd, J = 14.5 Hz, 4.4 Hz, 1H), 1.78 (dd, J = 14.5 Hz, 8.4
Hz, 1H), 1.43 (s, 9H), 1.36 (s, 6H); 13C NMR (CDCl3, 100
MHz), δC 173.1, 155.2, 80.1, 60.3, 52.4, 50.9, 43.0, 28.3, 26.3,
26.0; HRMS (ES) m/z: [M + Na]+ calcd for C12H22N4O4Na
309.1533; found 309.1536.
Methyl (2S)-3-(1-Azidocyclopentyl)-2-{[(tert-butoxy)-
carbonyl]amino}propanoate 34. Synthesis was achieved
by general procedure E using 1a (0.141 g, 0.52 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (7.371 g, 2.37 mmol),
NaN3 (0.109 g, 1.68 mmol), and NaBH4 (0.071 g, 1.77 mmol;
0.065 g, 1.72 mmol; 0.066 g, 1.74 mmol, 0.071 g, 1.88 mmol).
Puriﬁcation by ﬂash column chromatography (10% EtOAc in
petroleum ether (40−60), over silica) gave 34 as a colorless oil
(0.107 g, 0.34 mmol, 65%); [α]D
25 +15.1 (c 1.33, CHCl3);
νmax(thin ﬁlm, NaCl plates)/cm
−1 3364, 2968, 2919, 2880,
2102, 1748, 1717, 1513, 1451, 1438, 1393, 1367, 1254, 1208,
1166, 1055, 1023, 864, and 779; 1H NMR (CDCl3, 400 MHz)
δH 5.21 (d, J = 7.6 Hz, 1H), 4.44 (m, 1H), 3.75 (s, 3H), 2.18
(dd, J = 14.6 Hz, 4.9 Hz, 1H), 1.98 (dd, J = 14.3, J = 7.2 Hz,
1H), 1.92 (m, 2H), 1.82−1.66 (br m, 4H), 1.65−1.54 (br m,
2H), 1.44 (s, 9H); 13C NMR (CDCl3, 100 MHz), δC 173.1,
155.1, 80.0, 71.7, 52.5, 51.5, 40.8, 37.3, 37.2, 28.3, 23.4, 23.3;
HRMS (ES) m/z: [M + Na]+ calcd for C14H24N4O4Na
335.1690; found 335.1688.
Methyl (2S)-3-(1-Azidocyclohexyl)-2-{[(tert-butoxy)-
carbonyl]amino}propanoate 35. Synthesis was achieved
by general procedure E using 1b (0.142 g, 0.50 mmol),
Fe2(ox)3·6H2O (15 wt % solution) (7.371 g, 2.29 mmol),
NaN3 (0.145 g, 2.23 mmol), and NaBH4 (0.068 g, 1.80 mmol;
0.059 g, 1.56 mmol; 0.075 g, 1.98 mmol, 0.070 g, 1.85 mmol).
Puriﬁcation by ﬂash column chromatography (10% EtOAc in
petroleum ether (40−60), over silica) gave 35 as a colorless oil
(0.116 g, 0.36 mmol, 72%); [α]D
24 +4.4 (c 1.59, CHCl3);
νmax(thin ﬁlm, NaCl plates)/cm
−1 3363, 2977, 2934, 2861,
2103, 1747, 1717, 1513, 1450, 1438, 1390, 1367, 1254, 1211,
1164, 1051, 1024, 864, and 779; 1H NMR (CDCl3, 400 MHz)
δH 5.18 (d, J = 7.8 Hz, 1H), 4.42 (m, 1H), 3.74 (s, 3H), 2.06
(dd, J = 14.8 Hz, 4.5 Hz, 1H), 1.83 (dd, J = 14.8 Hz, 8.1 Hz,
1H), 1.72 (m, 2H), 1.59−1.24 (br m, 17H); 13C NMR
(CDCl3, 100 MHz), δC 173.2, 155.1, 80.0, 62.8, 52.5, 50.2,
41.5, 34.8, 34.3, 28.3, 25.1, 22.0; HRMS (ES) m/z: [M + Na]+
calcd for C15H26N4O4Na 349.1846; found 349.1851.
Methyl (2S)-5-Azido-2-{[(tert-butoxy)carbonyl]-
amino}-5-methylhexanoate 36. Synthesis was achieved by
general procedure E using 21 (0.134 g, 0.52 mmol), Fe2(ox)3·
6H2O (15 wt % solution) (7.585 g, 2.35 mmol), NaN3 (0.130
g, 2.00 mmol), and NaBH4 (0.061 g, 1.61 mmol; 0.074 g, 1.96
mmol; 0.066 g, 1.74 mmol; 0.076 g, 2.01 mmol). Puriﬁcation
by ﬂash column chromatography (10% EtOAc in petroleum
ether (40−60), over silica) gave the product 36 as a colorless
oil (0.108 g, 0.36 mmol, 69%); [α]D
24 +17.4 (c 1.09, CHCl3);
νmax(thin ﬁlm, NaCl plates)/cm
−1 3359, 2977, 2935, 2098,
1745, 1718, 1512, 1454, 1440, 1392, 1368, 1255, 1209, 1166,
1056, 1029, 867, 853, and 780; 1H NMR (CDCl3, 400 MHz)
δH 5.11 (d, J = 7.9 Hz, 1H), 4.29 (m, 1H), 3.74 (s, 3H), 1.91
(br m, 1H), 1.68 (br m, 1H), 1.53 (br m, 2H), 1.43 (s, 9H),
1.25 (s, 6H); 13C NMR (CDCl3, 100 MHz), δC 173.0, 155.3,
79.9, 61.0, 53.3, 52.4, 36.8, 28.3, 27.5, 26.0, 25.8; HRMS (ES)
m/z: [M + Na]+ calcd for C13H24N4O4Na 323.1690; found
323.1692.
Synthesis of 36 was also achieved by general procedure E
using 17 (0.128 g, 0.50 mmol), Fe2(ox)3·6H2O (15 wt %
solution) (6.733 g, 2.09 mmol), NaN3 (0.125 g, 1.92 mmol),
and NaBH4 (0.066 g, 1.74 mmol; 0.058 g, 1.53 mmol; 0.060 g,
1.59 mmol; 0.066 g, 1.74 mmol). Puriﬁcation by ﬂash column
chromatography (10% EtOAc in petroleum ether (40−60),
over silica) gave 36 as a colorless oil (0.130 g, 0.43 mmol,
86%), identical to that isolated above.
Methyl (2S,4RS)-4-Azido-2-{[(tert-butoxy)carbonyl]-
amino}-4-methylhexanoate 37. Synthesis was achieved by
general procedure E using (E/Z)-18 (7:1, E/Z) (0.131 g, 0.51
mmol), Fe2(ox)3·6H2O (15 wt % solution) (7.627 g, 2.37
mmol), NaN3 (0.126 g, 1.94 mmol), and NaBH4 (0.060 g, 1.59
mmol; 0.074 g, 1.96 mmol; 0.075 g, 1.98 mmol; 0.078 g, 2.06
mmol). Puriﬁcation by ﬂash column chromatography (10%
EtOAc in petroleum ether (40−60), over silica) gave 37 as a
colorless oil, which is a mixture of diastereomers (0.096 g, 0.32
mmol, 63%); νmax(thin ﬁlm, NaCl plates)/cm
−1 3361, 2977,
2935, 2883, 2105, 1748, 1716, 1514, 1458, 1437, 1390, 1367,
1255, 1205, 1166, 1056, 1025, 862, and 779; 1H NMR
(CDCl3, 400 MHz) δH 5.20 (d, J = 7.8 Hz, 1H), 4.39 (m, 1H),
3.75 (s, 3H), 1.95 (m, 1H), 1.76 (m, 1H), 1.65 (m, 2H), 1.44
(s, 9H), 1.33 (s, 3H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR
(CDCl3, 100 MHz), δC 173.2, 155.2, 80.1, 63.1, 52.5, 50.7,
50.6, 41.0, 40.5, 32.8, 32.4, 28.3, 22.6, 22.4, 8.4, 8.3; HRMS
(ES) m/z: [M + H]+ calcd for C13H25N4O4 301.1870; found
301.1872.
General Procedure F, Azide Reduction. The azido
amino acid was dissolved in EtOAc, 10 wt % Pd on carbon was
added (≈20 wt %), and the mixture was stirred overnight
under an atmosphere of hydrogen. The product was puriﬁed
by ﬂash column chromatography (EtOAc in petroleum ether
(40−60) mixtures over silica).
tert-Butyl N-[(3S)-5,5-Dimethyl-2-oxopyrrolidin-3-yl]-
carbamate 38. Synthesis was achieved by general procedure
F using 33 (0.138 g, 0.48 mmol), EtOAc (4 mL), Pd/C 10 wt
% (0.037 g, ≈20 wt %). Puriﬁcation by ﬂash column
chromatography (50% EtOAc in petroleum ether (40−60),
over silica) gave 38 as a white solid (0.109 g, 0.48 mmol,
>99%); mp 121−123 °C; [α]D
25 +27.4 (c 1.09, CHCl3);
νmax(thin ﬁlm, NaCl plates)/cm
−1 3284, 2975, 2933, 2883,
1705, 1528, 1455, 1420, 1392, 1368, 1327, 1292, 1247, 1169,
1056, 1028, 1001, 979, 885, 835, and 755; 1H NMR (CDCl3,
400 MHz) δH 7.11 (br s, 1H), 5.24 (br d, J = 4.3 Hz, 1H), 4.35
(br m, 1H), 2.54 (br t, J = 8.3 Hz, 1H), 1.75 (br t, J = 11.1 Hz,
1H), 1.43 (s, 9H), 1.31 (s, 3H), 1.27 (s, 3H); 13C NMR
(CDCl3, 100 MHz), δC 174.2, 155.9, 79.8, 53.9, 52.1, 44.2,
29.9, 28.5, 28.3; HRMS (ES) m/z: [M + Na]+ calcd for
C11H20N2O3Na 251.1366; found 251.1366.
tert-Butyl N-[(3S)-2-Oxo-1-azaspiro[4.4]nonan-3-yl]-
carbamate 39. Synthesis was achieved by general procedure
F using 34 (0.161 g, 0.52 mmol), EtOAc (4 mL), Pd/C 10 wt
% (0.038 g, ≈20 wt %). Puriﬁcation by ﬂash column
chromatography (50% EtOAc in petroleum ether (40−60),
over silica) gave 39 as a colorless oil (0.121 g, 0.48 mmol,
92%); [α]D
25 +13.9 (c 1.22, CHCl3); νmax(thin ﬁlm, NaCl
plates)/cm−1 3276, 2967, 2874, 1702, 1523, 1454, 1391, 1366,
1323, 1285, 1248, 1168, 1062, 1028, 1007, 839, and 753; 1H
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NMR (CDCl3, 400 MHz) δH 7.57 (br s, 1H), 5.28 (br s, 1H),
4.29 (m, 1H), 2.61 (br t, J = 9.4 Hz, 1H), 1.86−1.63 (br m,
9H), 1.42 (s, 9H); 13C NMR (CDCl3, 100 MHz), δC 174.6,
160.0, 79.7, 64.0, 52.2, 42.8, 39.4, 38.4, 28.3, 23.5, 22.7; HRMS
(ES) m/z: [M + Na]+ calcd for C13H22N2O3Na 277.1523;
found 277.1525.
tert-Butyl N-[(3S)-2-Oxo-1-azaspiro[4.5]decan-3-yl]-
carbamate 40. Synthesis was achieved by general procedure
F using 35 (0.106 g, 0.32 mmol), EtOAc (5 mL), Pd/C 10 wt
% (0.023 g, ≈20 wt %). Puriﬁcation by ﬂash column
chromatography (40% EtOAc in petroleum ether (40−60),
over silica) gave a colorless oil that solidiﬁed on standing.
Recrystallization from hot Et2O/pentane (1:1) gave com-
pound 40 (0.079 g, 0.29 mmol, 91%); mp 160−163 °C; [α]D
24
+24.1 (c 1.14, CHCl3); νmax(thin ﬁlm, NaCl plates)/cm
−1
3231, 3029, 3006, 2978, 2932, 2857, 1702, 1501, 1453, 1391,
1366, 1332, 1293, 1280, 1246, 1170, 1064, 973, 854, and 760;
1H NMR (CDCl3, 400 MHz) δH 7.49 (br s, 1H), 5.24 (br s,
1H), 4.29 (br m, 1H), 2.67 (br t, J = 9.7 Hz, 1H), 1.62−1.49
(br m, 11H), 1.43 (s, 9H); 13C NMR (CDCl3, 100 MHz), δC
174.3, 156.0, 79.8, 56.8, 51.5, 41.7, 39.4, 37.3, 28.3, 25.0, 23.0,
22.7; HRMS (ES) m/z: [M + Na]+ calcd for C14H24N2O3Na
291.1679; found 291.1679.
tert-Butyl N-[(3S)-6,6-Dimethyl-2-oxopiperidin-3-yl]-
carbamate 41. Synthesis was achieved by general procedure
F using 36 (0.180 g, 0.60 mmol), EtOAc (3 mL), Pd/C 10 wt
% (0.037 g, ≈20 wt %). Puriﬁcation by ﬂash column
chromatography (50% EtOAc in petroleum ether (40−60),
over silica) gave compound 41 as a white solid (0.144 g, 0.59
mmol, 98%); mp 124−127 °C; [α]D
25 +47.8 (c 1.36, CHCl3);
νmax(thin ﬁlm, NaCl plates)/cm
−1 3285, 3230, 2974, 2935,
1705, 1665, 1490, 1459, 1416, 1367, 1344, 1312, 1249, 1164,
1076, 1054, 1024, 971, 831, and 756; 1H NMR (CDCl3, 400
MHz) δH 5.82 (br s, 1H), 5.46 (br s, 1H), 3.96 (m, 1H), 2.40
(m, 1H), 1.75 (m, 3H), 1.46 (s, 9H), 1.29 (s, 3H), 1.27 (s,
3H); 13C NMR (CDCl3, 100 MHz), δC 170.8, 156.0, 79.4,
53.1, 51.4, 34.4, 31.6, 29.7, 28.3, 25.3; HRMS (ES) m/z: [M +
H]+ calcd for C12H23N2O3 243.1705; found 243.1703.
General Procedure G, Radical Hydroxylation. The
amino acid was dissolved in MeCN (20 mL), and Fe2(ox)3 (15
wt % solution) and deionized water (18 mL) were added. The
mixture was stirred, and a ﬂow of air passed through the
solution. NaBH4 was added in eight portions with ≈2 min
between each addition. The reaction mixture was then stirred
for 45 min. Conc. NH4OH solution (4 mL) was added, and
the reaction mixture stirred for 1 min. The aqueous phase was
extracted with 5% MeOH in CH2Cl2 (3 × 50 mL). The
combined organic phases were dried with Na2SO4, ﬁltered, and
concentrated under reduced pressure. The product was
puriﬁed by ﬂash column chromatography (EtOAc in
petroleum ether (40−60) mixtures over silica).
tert-Butyl N-[(3S)-5,5-Dimethyl-2-oxooxolan-3-yl]-
carbamate 42. Synthesis was achieved by general procedure
G using 16 (0.133 g, 0.55 mmol), Fe2(ox)3·6H2O (15 wt %
solution) (7.701 g, 2.39 mmol), and NaBH4 (0.027 g, 0.71
mmol; 0.0306 g, 0.81 mmol; 0.0228 g, 0.60 mmol; 0.039 g,
1.03 mmol; 0.031 g, 0.82 mmol; 0.036 g, 0.95 mmol; 0.025 g,
0.66 mmol; 0.037 g, 0.98 mmol). Puriﬁcation by ﬂash column
chromatography (15−30% EtOAc in petroleum ether (40−
60), over silica) gave 42 as a white solid (0.055 g, 0.24 mmol,
44%); mp 110−113 °C; [α]D
24 +20.0 (c 0.95, CHCl3);
νmax(thin ﬁlm, NaCl plates)/cm
−1 3317, 2981, 2937, 1759,
1708, 1531, 1453, 1375, 1368, 1307, 1272, 1249, 1207, 1158,
1109, 1001, 973, 952, 923, 885, and 809; 1H NMR (CDCl3,
400 MHz) δH 5.12 (br s, 1H), 4.57 (br m, 1H), 2.67 (apparent
t, J = 10.2 Hz, 1H), 1.97 (apparent t, J = 11.9 Hz, 1H), 1.50 (s,
3H), 1.46 (s, 9H), 1.43 (s, 3H); 13C NMR (CDCl3, 100
MHz), δC 174.6, 155.5, 82.4, 80.5, 51.3, 42.6, 29.0, 28.3, 26.9;
HRMS (ES) m/z: [M + Na]+ calcd for C11H19NO4Na
252.1206; found 252.1209.
Methyl (2S)-2-{[(tert-Butoxy)carbonyl]amino}-5-hy-
droxy-5-methylhexanoate 43. Synthesis was achieved by
general procedure G using 17 (0.149 g, 0.58 mmol), Fe2(ox)3·
6H2O (15 wt % solution) (7.117 g, 2.21 mmol), and NaBH4
(0.031 g, 0.82 mmol; 0.035 g, 0.93 mmol; 0.031 g, 0.82 mmol;
0.032 g, 0.85 mmol; 0.032 g, 0.85 mmol; 0.039 g, 1.03 mmol;
0.038 g, 1.00 mmol; 0.027 g, 0.71 mmol). Puriﬁcation by ﬂash
column chromatography (30−100% EtOAc in petroleum ether
(40−60), over silica) gave 43 as a colorless oil (0.099 g, 0.36
mmol, 62%); [α]D
24 +10.1 (c 1.09, CHCl3); νmax(thin ﬁlm,
NaCl plates)/cm−1 3439, 3373, 2975, 2934, 1738, 1712, 1521,
1455, 1437, 1392, 1367, 1273, 1252, 1208, 1165, 1054, 1028,
914, and 858; 1H NMR (CDCl3, 400 MHz) δH 5.20 (br m,
1H), 4.32 (br m, 1H), 3.74 (s, 3H), 1.98−1.67 (br m, 3H),
1.55−1.44 (br m, 11H), 1.21 (s, 6H); 13C NMR (CDCl3, 100
MHz), δC 173.4, 155.4, 79.9, 70.4, 53.6, 52.3, 38.8, 29.4, 29.2,
28.3, 27.6; HRMS (ES) m/z: [M + Na]+ calcd for
C13H25NO5Na 298.1625; found 298.1626.
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